Europejskie Centrum Zdrowia Otwock Sp. z o.o.

This site conducts a broad range of cancer studies focused on advanced and metastatic disease, with work spanning renal cell carcinoma, colorectal cancer, breast cancer, prostate cancer, and other difficult-to-treat solid tumors. The trials are mainly designed to test new treatment combinations and compare them with current standards of care, with the aim of improving disease control and extending survival.

• Advanced and metastatic renal cell carcinoma, including clear cell and papillary subtypes
• Colorectal cancer with and without specific genetic changes such as KRAS G12C
• Breast cancer, especially hormone receptor-positive and HER2-negative disease
• Prostate cancer, including metastatic castration-resistant disease
• Studies in gastric, gastroesophageal junction, ovarian, lung, and hepatocellular cancers

Research here often explores immunotherapy-based combinations, targeted therapies, and new treatment strategies for patients whose disease has progressed after earlier therapy.

The site also supports important studies in pulmonary arterial hypertension and related cardiovascular conditions. These trials are aimed at improving symptoms, slowing disease progression, and evaluating the long-term safety of emerging therapies used alongside background treatment.

• Pulmonary arterial hypertension in newly diagnosed and long-term treated patients
• Pulmonary hypertension associated with interstitial lung disease
• Research on therapies intended to improve hemodynamics and reduce pulmonary vascular resistance
• Follow-up studies focused on the safety and tolerability of ongoing treatment

This area reflects a strong interest in better management of serious vascular disease through both symptom control and longer-term outcome improvement.

Several studies at the hospital examine hormone-sensitive and metabolism-related aspects of cancer care, especially in breast cancer and prostate cancer. The research is centered on evaluating whether newer endocrine-based or pathway-targeted approaches can improve effectiveness compared with established treatment options.

• ER-positive, HER2-negative breast cancer in early and advanced settings
• Metastatic castration-resistant prostate cancer and hormone-sensitive prostate cancer
• Trials assessing treatment choices for patients with high risk of recurrence or prior therapy resistance
• Studies combining endocrine therapy with newer targeted agents

This research supports more personalized care for patients whose tumors are driven by hormone signaling or related biological pathways.

A major part of the trial portfolio involves testing novel immunotherapy and targeted therapy combinations across multiple advanced cancers. These studies aim to determine whether new agents can improve response rates, delay progression, and offer better options after standard treatments stop working.

• Renal, colorectal, gastric, and lung cancers in advanced stages
• Combination approaches involving checkpoint inhibitors and targeted medicines
• Research in ovarian cancer and other solid tumors with limited treatment options
• Studies designed to identify promising new regimens for later-line disease

The Europejskie Centrum Zdrowia Otwock contributes to the development of next-generation cancer therapies by evaluating whether these approaches can outperform current standards.

Some trials focus on patients with advanced malignancies who need continued access to promising therapies or new options after prior study participation. This includes research that supports ongoing treatment, broader access to investigational medicines, and assessment of long-term benefit and safety.

• Advanced solid tumors and metastatic disease across several tumor types
• Continuation studies for participants already receiving investigational therapy
• Research aimed at maintaining treatment benefit over time
• Evaluation of safety, tolerability, and real-world treatment continuity

These studies help extend the clinical research pathway for patients with limited standard options and ongoing treatment needs.